title: Radioactive ¹²⁵I seed inhibits the cell growth, migration, and invasion of nasopharyngeal carcinoma by triggering DNA damage and inactivating VEGF-A/ERK signaling.
abstract: Although radiotherapy technology has progressed rapidly in the past decade, the inefficiency of radiation and cancer cell resistance mean that the 5-year survival rate of patients with nasopharyngeal carcinoma (NPC) is low. Radioactive (125)I seed implantation has received increasing attention as a clinical treatment for cancers. Vascular endothelial growth factor-A (VEGF-A) is one of the most important members of the VEGF family and plays an important role in cell migration through the extracellular-signal-regulated kinase (ERK) pathway. Here we show that radioactive (125)I seeds more effectively inhibit NPC cell growth through DNA damage and subsequent induction of apoptosis, compared with X-ray irradiation. Moreover, cell migration was effectively inhibited by (125)I seed irradiation through VEGF-A/ERK inactivation. VEGF-A pretreatment significantly blocked (125)I seed irradiation-induced inhibition of cell migration by recovering the levels of phosphorylated ERK (p-ERK) protein. Interestingly, in vivo study results confirmed that (125)I seed irradiation was more effective in inhibiting tumor growth than X-ray irradiation. Taken together, these results suggest that radioactive (125)I seeds exert novel anticancer activity by triggering DNA damage and inactivating VEGF-A/ERK signaling. Our finding provides evidence for the efficacy of (125)I seeds for treating NPC patients, especially those with local recurrence.
authors.affiliation: Cancer Research Institute, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China ; Department of Oncology, Armed Police Hospital of Guangdong Province, Guangzhou, Guangdong Province, People's Republic of China.
authors.forename: Yunhong
authors.initials: Y
authors.lastname: Tian
authors.forename: Qiang
authors.initials: Q
authors.lastname: Xie
authors.forename: Yunming
authors.initials: Y
authors.lastname: Tian
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Zuoping
authors.initials: Z
authors.lastname: Huang
authors.forename: Cundong
authors.initials: C
authors.lastname: Fan
authors.forename: Bing
authors.initials: B
authors.lastname: Hou
authors.forename: Dan
authors.initials: D
authors.lastname: Sun
authors.forename: Kaitai
authors.initials: K
authors.lastname: Yao
authors.forename: Tianfeng
authors.initials: T
authors.lastname: Chen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000528:radiation effects; D002277:Carcinoma; D059447:Cell Cycle Checkpoints / Q000528:radiation effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000528:radiation effects; D049109:Cell Proliferation / Q000528:radiation effects; D004249:DNA Damage / Q000528:radiation effects*; D004195:Disease Models, Animal; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D051379:Mice; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D009361:Neoplasm Invasiveness; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000528:radiation effects*; D047368:Tumor Burden / Q000528:radiation effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D014965:X-Rays; D023041:Xenograft Model Antitumor Assays
chemical_list: D007457:Iodine Radioisotopes; D017382:Reactive Oxygen Species; D042461:Vascular Endothelial Growth Factor A; D048049:Extracellular Signal-Regulated MAP Kinases
references.citation: Radiother Oncol. 2004 Feb;70(2):177-82
references.pmid: 15028405
references.citation: Oncogene. 2003 Sep 1;22(37):5774-83
references.pmid: 12947385
references.citation: J Exp Clin Cancer Res. 2009 Jan 29;28:12
references.pmid: 19175942
references.citation: Head Neck. 2013 Sep;35(9):1238-47
references.pmid: 22972415
references.citation: PLoS One. 2013;8(2):e56381
references.pmid: 23418564
references.citation: J Biol Chem. 2011 Mar 18;286(11):9097-106
references.pmid: 21212275
references.citation: Cancer Biother Radiopharm. 2009 Aug;24(4):409-16
references.pmid: 19694575
references.citation: Cell Signal. 2012 Jun;24(6):1116-25
references.pmid: 22326662
references.citation: Br J Cancer. 2008 Feb 12;98(3):523-8
references.pmid: 18231106
references.citation: Int J Cancer. 2006 Oct 1;119(7):1519-29
references.pmid: 16671089
references.citation: PLoS One. 2012;7(8):e42890
references.pmid: 22912759
references.citation: Radiat Res. 2002 Sep;158(3):311-8
references.pmid: 12175308
references.citation: World J Surg. 2009 Apr;33(4):661-6
references.pmid: 19034564
references.citation: PLoS One. 2011;6(9):e25213
references.pmid: 21980400
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900
references.pmid: 15279774
references.citation: Cancer Res. 1992 Sep 1;52(17):4787-90
references.pmid: 1511442
references.citation: Eur J Cancer. 2012 Dec;48(18):3422-8
references.pmid: 22835782
references.citation: J Transl Med. 2008 Jan 03;6:1
references.pmid: 18171482
references.citation: Int J Colorectal Dis. 2009 Apr;24(4):391-9
references.pmid: 19084969
references.citation: Integr Cancer Ther. 2010 Mar;9(1):59-65
references.pmid: 20150222
references.citation: Oncogene. 2010 Jul 29;29(30):4317-29
references.pmid: 20498628
references.citation: PLoS One. 2013;8(2):e57036
references.pmid: 23437304
references.citation: Br J Cancer. 2007 Oct 22;97(8):1090-8
references.pmid: 17912247
references.citation: Cancer Invest. 2012 Mar;30(3):236-42
references.pmid: 22360363
references.citation: Eur Arch Otorhinolaryngol. 2010 Dec;267(12):1811-24
references.pmid: 20865269
references.citation: Cancer Res. 2001 Mar 15;61(6):2744-50
references.pmid: 11289157
references.citation: Radiat Oncol. 2012 Feb 22;7:25
references.pmid: 22356893
references.citation: Cancer Res. 2005 Jan 1;65(1):113-20
references.pmid: 15665286
references.citation: J Biol Chem. 2009 Mar 27;284(13):8786-96
references.pmid: 19136554
references.citation: Cancer Biol Ther. 2010 Jun 15;9(12):959-66
references.pmid: 20873398
references.citation: Cancer J. 2002 Jan-Feb;8(1):47-54
references.pmid: 11895203
references.citation: Radiother Oncol. 2012 Sep;104(3):272-8
references.pmid: 22938727
references.citation: Int J Biol Sci. 2011 Feb 14;7(2):168-79
references.pmid: 21383953
references.citation: Biomed Pharmacother. 2009 Feb;63(2):105-13
references.pmid: 18511231
references.citation: Cancer Cell. 2004 May;5(5):429-41
references.pmid: 15144951
references.citation: Crit Rev Biochem Mol Biol. 2011 Aug;46(4):271-83
references.pmid: 21524151
references.citation: PLoS One. 2012;7(8):e43898
references.pmid: 22952803
references.citation: PLoS One. 2012;7(7):e37512
references.pmid: 22815682